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Abstract 
Parkinson’s disease (PD) is a debilitating movement disorder typically associated with the 
accumulation of intracytoplasmic aggregate-prone protein deposits. Over recent years, increasing 
evidence has led to the suggestion that the mutations underlying certain forms of PD impair 
autophagy. Autophagy is a degradative pathway that delivers cytoplasmic content to lysosomes for 
degradation and represents a major route for degradation of aggregated cellular proteins and 
dysfunctional organelles. Autophagy upregulation is a promising therapeutic strategy that is being 
explored for its potential to protect cells against the toxicity of aggregate-prone proteins in 
neurodegenerative diseases. Here we describe how the mutations in different subtypes of PD can 
affect different stages of autophagy.  
 
Abbreviations 
AD, Alzheimer’s disease; AMPK, AMP activated protein kinase; ATG, autophagy related genes; CMA, 
chaperone-mediated autophagy; FIP200, focal adhesion kinase family interacting protein of 200 kDa; GBA, 
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glucocerebrosidase; HD, Huntington’s disease; MTOC, microtubule organizing center; mTORC1, 
mammalian target of rapamycin complex 1; PD, Parkinson’s disease; PE, phosphatidylethanolamine; PI3P, 
phosphatidylinositol 3-phosphate; SNCA, synuclein; TFEB, transcription factor EB; ULK1, mammalian 
homologs of the C. elegans uncoordinated-51 kinase 1; WIPI, WD repeat domain phosphoinositide-
interacting protein.  
 
Introduction 
Autophagy is an evolutionarily conserved degradation pathway responsible for digestion and 
recycling of most long-lived intracytoplasmic proteins and organelles. Autophagy is subcategorized 
into three types – microautophagy, chaperone-mediated autophagy (CMA) and macroautophagy.  
Microautophagy involves degradation of cytosolic contents via small invaginations in the lysosome 
membrane (1), while CMA involves selective translocation of cytoplasmic proteins with a KFERQ-
like peptide motif into the lysosomal lumen for degradation (2). Macroautophagy (hereafter called 
autophagy and the focus of this review) is characterized by engulfment of cytoplasmic cargo by a 
double-membraned cup-shaped transient structure known as the phagophore. After the 
phagophore expands and its edges close, the resulting vesicle is known as an autophagosome. 
Autophagosomes then fuse with lysosomes resulting in degradation of the autophagosomal 
contents (Figure 1). This series of events is regulated by an array of proteins called autophagy-
related (ATG) proteins.  
It has become evident in recent years that both selective and non-selective types of autophagy 
exist and maintain degradation of cargo material, such as aggregate-prone proteins (aggrephagy) 
and damaged organelles, such as mitochondria (mitophagy), peroxisomes (pexophagy) and 
endoplasmic reticulum (ER-phagy) (3). Mutations underlying various neurodegenerative diseases 
that manifest with intracytoplasmic protein aggregates have been shown to affect the clearance of 
these substrates by compromising autophagy (4). In the present review, we focus on autophagy 
impairment in Parkinson’s disease (PD). Autophagy upregulation has been studied extensively as 
a promising strategy for treatment of PD. Therefore, a more refined distinction between the classes 
of autophagy defects underlying certain subtypes of PD may be helpful in strategizing effective 
treatments for this condition.   
 
The Autophagic Machinery 
Autophagy is essential for cellular health and is activated as a response to the nutrient state of the 
cell. In basal conditions, the presence of nutrients, growth factors and AMP/ATP levels are sensed 
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by the Rag/Ragulator complex, tyrosine kinase receptors and AMP-dependent protein kinase 
(AMPK), leading to activation of the primordial negative autophagy regulator, mammalian target of 
rapamycin complex 1 (mTORC1). Active mTORC1 inhibits the ULK1-ATG13-FIP200 complex 
through phosphorylation of ULK1/2 and ATG13. The ULK complex is the most upstream unit 
amongst the autophagy proteins and plays a crucial role in autophagy initiation. The inhibition of 
this complex results in suppression of autophagosome formation (5–7).  
 
During cellular starvation, autophagy activation provides building blocks from degraded 
macromolecules. As a response to low nutrient levels, mTORC1 is inhibited leading to 
dephosphorylation of the ULK complex, causing activation of the class III PI3-kinase, VPS34. 
VPS34 is recruited to the phagophore initiation site where it interacts with VPS15, ATG14, and 
Beclin 1 to generate phosphatidylinositol 3-phosphate (PI3P), an essential lipid component of the 
autophagosomes. The presence of PI3P on nascent autophagosomes facilitates the recruitment of 
PI3P-binding proteins, such as WD repeat domain phosphoinositide-interacting protein 2 (WIPI2), 
which is crucial for recruitment of downstream autophagic proteins (8–10).  
 
Next, phagophore elongation occurs, mediated by two specialized ubiquitin-like conjugation 
systems, with membranes obtained from the endoplasmic reticulum, Golgi, mitochondria and 
plasma membrane (11–13). The first system involves a conjugation reaction between ATG12 and 
ATG5 mediated by the E1- and E2-like enzymes ATG7 and ATG10, respectively. The subsequent 
non-covalent binding between ATG12-ATG5 complex and ATG16L1 enables the resulting complex 
to associate with pre-autophagosomal membranes to assist their elongation by recruiting LC3 and 
its family members. Membrane association of LC3 is mediated by the second conjugation system. 
After the C termini of LC3 family members are cleaved by ATG4, exposing glycine residues, LC3 
family proteins can be conjugated to phosphatidylethanolamine (PE) in the preautophagosomal 
membranes via a reaction mediated by ATG7, ATG3, and ATG12-ATG5-ATG16L1. The lipid-
conjugated LC3 is known as LC3-II. The transmembrane protein mATG9 may assist in the 
expansion of the phagophore by providing further lipids (14,15).  
 
Following the completion of autophagosome formation, these vesicles are transported along 
microtubules to the microtubule organizing center (MTOC), where lysosomes are clustered. This 
facilitates autophagosome-lysosome fusion, which results in the degradation of the 
autophagosomal contents by lysosomal acid hydrolases. The expression of lysosomal enzymes is 
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regulated by the transcription factor EB (TFEB), which is the master regulator of autophagy and 
lysosomal genes. Translocation of TFEB to the nucleus enables its transcriptional activity, 
autophagosome formation and autophagosome-lysosome fusion (16). Studies have shown that 
overexpression of TFEB improves degradation of complex molecules (17,18).  
 
Autophagy and Parkinson’s Disease  
Basal autophagy is essential for maintaining neuronal homeostasis, since neurons are particularly 
susceptible to the accumulation of defective organelles and proteins due to their postmitotic nature. 
The importance of autophagy for the nervous system was confirmed by studies in which 
suppression of autophagy in atg7- and atg5-deficient mice led to phenotypes similar to those 
observed in neurodegenerative diseases, such as progressive motor impairment and 
intracytoplasmic inclusion bodies (19,20). This supports earlier studies showing the importance of 
autophagy in the clearance of aggregate-prone proteins in models of PD (21). Consistent with this, 
in vivo and in vitro studies, described below, have shown that autophagic dysfunction plays a likely 
role in disease pathogenesis.  
 
PD is the most common neurodegenerative movement disorder. It is characterized by motor 
deficits and non-motor symptoms, like mood disorders and cognitive impairment. PD pathology is 
characterised by progressive neuronal loss which is observed in many areas but is most marked in 
dopaminergic neurons in the substantia nigra, and the presence of intraneuronal inclusions known 
as Lewy bodies (LBs) and Lewy neurites enriched with filamentous forms of α-synuclein (α-syn) 
(22,23). This protein, encoded by the SNCA gene, has been extensively studied. Multiplications of 
the SNCA locus cause autosomal dominant forms of PD. The identification of familial cases with 
SNCA multiplications revealed a strong correlation between levels of α-syn and disease severity 
(24). Although these findings show that increased levels of α-syn is critical for disease severity, α-
syn mRNA levels do not consistently change in sporadic PD cases. Since α-syn degradation is 
maintained by multiple degradative routes including autophagy (21), chaperone-mediated 
autophagy (CMA) (25) and the endolysosomal pathway (26), impaired clearance of α-syn is 
suggested to be an underlying mechanism responsible for α-syn accumulation and aggregation in 
sporadic cases of PD.  
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Initial genetic studies led to the discovery of causal mutations in PD, which were subjected to 
extensive research and many were found to have functions related to autophagy. These can be 
subdivided into mutations that affect mitophagy or cause trafficking or lysosomal defects (Figure 
2). Consistent  with the converging evidence pointing towards impaired autophagy in PD, a recent 
meta-analysis of genome-wide association studies (GWAS) has identified novel PD risk loci that 
may play roles in autophagy and lysosomal function (27).  
 
Mitophagy defects in PD  
Mitochondria are essential for maintaining critical cellular functions, such as generating energy. 
Genetic linkage studies identified mutations in phosphatase and tensin homologue-induced 
putative kinase 1 (PINK1 or PARK6) and Parkin (PARK2) in autosomal recessive juvenile 
Parkinson’s disease. PINK1 and Parkin coordinately regulate the autophagic degradation of 
mitochondria (mitophagy), which is a crucial quality control that removes defective mitochondria 
from the cells, and these two proteins were first shown in D. melanogaster studies to act via the 
same pathway (28–30). Under normal conditions, the mitochondrial serine/threonine kinase PINK1 
is recruited to the inner mitochondrial membrane (IMM) by the translocase of the outer membrane 
(TOM) complex and the translocase of the inner membrane (TIM23) complex. It is then cleaved by 
the mitochondrial processing peptidase (MPP) and presenilin-associated rhomboid-like protein 
(PARL) before it is translocated back to the cytoplasm. The cleaved PINK1 is ubiquitinated and 
consequently degraded by the 26S proteasome. However, when mitochondria are depolarised or 
damaged, PINK1 accumulates on the outer mitochondrial membrane (OMM), where it 
phosphorylates parkin and ubiquitin on Ser65, which in turn leads to activation of Parkin (31). 
Activated Parkin forms polyubiquitin chains on damaged mitochondria, which are then 
phosphorylated by PINK1. The phospho-polyubiquitination of dysfunctional mitochondria enables 
the binding of autophagy receptors, such as NDP52 and Optineurin, which serve as signals for 
autophagic clearance by recruiting LC3-containing phagophores (3,32,33).  
 
The function of these PD-related mitophagy effectors have been subject to extensive research. 
Interestingly, deletion of parkin in mouse models did not cause an obvious behavioural phenotype 
(34–36), although it impaired striatal neuron mitochondria and caused a deficit in evoked dopamine 
release (37). PINK1 deletion also resulted in striatal mitochondria defects and increased sensitivity 
to oxidative stress (38). However, a study in which parkin is deleted in adult mice described age-
dependent loss of dopamine neurons, suggesting the existence of a compensatory mechanism in 
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germline knockouts (39). The importance of Parkin for ensuring mitochondrial quality was further 
shown in a study using the so-called mutator mice, in which mitochondrial function is gradually 
impaired due to an accelerated generation of mtDNA mutations. The absence of Parkin in the 
mutator mice led to degeneration of dopaminergic neurons. The motor deficit that appeared in the 
Parkin-mutator mice was reversed by administration of L-DOPA (40). A recent study in DA neurons 
derived from iPSCs with Parkin or PINK1 mutations show impaired ubiquitination of mitochondria  
and may explain how these mutations cause reduced clearance of damaged mitochondria (41).   
Mutations in the F-box protein 7 (FBXO7) gene (PARK15) are associated with a severe form of 
juvenile onset PD. FBXO7 interacts with PINK1 and Parkin and helps facilitate Parkin-mediated 
mitophagy (42). PD-associated FBXO7 mutations in D. melanogaster led to mitochondrial toxicity 
as a result of FBXO7 aggregation in the mitochondria (43). 
 
Trafficking defects in PD  
It is well-established that α-syn plays a substantial role in PD pathogenicity. The presence of α-syn 
inclusion bodies affects autophagosome maturation and fusion with lysosomes, resulting in 
decreased protein degradation (44). In vitro studies show that the presence of α-syn inclusions 
specifically inhibits transport of endocytic and autophagic vesicles (45). Additionally, 
overexpression of α-syn in vitro and in vivo leads to compromised autophagosome biogenesis by 
inhibiting Rab1 causing mislocalization of mATG9 (46).  
 
Autophagy is also impaired by the vacuolar protein sorting-associated protein 35 (VPS35) D620N 
mutation causing an autosomal dominant form of PD. VPS35 is a component of the retromer 
complex, which is required for the recruitment of the actin nucleation-promoting WASP and Scar 
homolog (WASH) complex to endosomes to facilitate protein sorting (47) and trafficking of 
transmembrane receptors within the endosome-to-Golgi retrieval pathway (48). D620N VPS35 
associates poorly with the WASH complex and impairs the recruitment, which causes mATG9 
mislocalization and inhibition of autophagosome formation (49). Interestingly, the effects of the 
VPS35 D620N mutation on autophagy were not mimicked by loss of VPS35 in this study and were 
unrelated to retrograde endosome-to-Golgi trafficking, suggesting that the point mutation may 
affect only a subset of VPS35 functions. Studies suggest that VPS35 interacts with Parkin (50), 
which in turn ubiquitinates VPS35 in human neuroblastoma cells (51). Interestingly, loss of Parkin 
led to decreased membrane association of VPS35 (52). Additionally, the D620N VPS35 mutation 
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has been suggested to affect the endolysosomal pathway (53) leading to increased α-syn 
aggregation (54). A study conducted in α-syn expressing mice showed a reduction in α-syn 
inclusions and reduced neuronal loss when delivering lentiviral WT VPS35, in contrast to lentiviral 
D620N VPS35 (55).  
 
Lysosomal defects in PD 
Degradation of α-syn can be maintained via multiple degradative routes. However, regardless of 
the route, functioning lysosomes are required for the degradation. The importance of lysosomal 
function for α-syn clearance was suggested by a study conducted in both cathepsin D (CatD) 
deficient mice and C. elegans showing that not only does CatD deficiency impair autophagy, but it 
also causes accumulation of α-syn aggregates in the nervous system (56). As outlined below, 
there is increasing evidence of lysosomal defects in PD. 
 
Autosomal dominant mutations in the gene LRRK2, which encodes a multidomain protein with 
multiple functions, are among the most common genetic determinants underlying familial forms of 
PD. The causative role of LRRK2 in PD has been studied extensively and many studies suggest 
that LRRK2 is involved in endosome-to-lysosome trafficking. A study in D. melanogaster showed 
that the LRRK2 homolog, Lrrk, is localized on late endosomal and lysosomal membranes and that 
Lrrk physically binds to the late endosomal protein Rab7. Overexpression of mutant GS lrrk, 
analogous to the most common PD causing mutation in human LRRK2 (G2019S), led to defective 
lysosomal positioning mediated by Rab7 (57). Further studies in D. melanogaster showed that loss 
of Lrrk function led to the accumulation of enlarged lysosomes containing undigested content, 
indicating defective lysosomal degradation. Constitutive activation of Rab9, which promotes 
endosomal recycling, suppressed the lysosomal dysfunction caused by the G2019S lrrk mutation 
(58). Additionally, endolysosomal sorting defects were observed in primary rodent neurons 
expressing G2019S LRRK2, leading to VPS35 retromer complex deficiency (59). The notion that 
LRRK2 is involved in regulating lysosome function is further supported by a study conducted in 
mice and in primary cells. In this study, expression of G2019S LRRK2 led to production of 
enlarged lysosomes and a reduction in lysosomal pH. The perturbations in lysosomal pH and 
morphology were rescued by selective inhibition of LRRK2’s kinase activity. This suggests that the 
G2019S LRRK2 mutation promotes lysosomal dysfunction (60).  
 
The role of LRRK2 in autophagy has been controversial, as LRRK2 knockdown has been shown to 
both reduce and potentiate autophagic flux (61,62). Studies in mutant fibroblasts showed both 
8 
 
increased levels of autophagy through activation of the MEK/ERK pathway in G2019S-LRRK2 
cells (63) and decreased responses to autophagy induction in R1441G, Y1699C and G2019S-
LRRK2 cells. Studies of PD fibroblast-derived neurons (G2019S-LRRK2) also showed impairment 
of autophagy, however at the stage of autophagosome clearance level rather than induction. A 
recent study in an astrocyte cell model proposes that the kinase activity of LRRK2 negatively 
regulates autophagy, as chemical inhibition of LRRK2 kinase activity led to induction of non-
canonical, mTOR/ULK1-independent, Beclin 1-dependent autophagy (64). LRRK2 studies have 
been complicated by the existence of a wide range of LRRK2 models and LRRK2 modulators and 
the role of LRRK2 in autophagy remains yet to be clarified.  
 
Heterozygous mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA) 
are the most common known genetic risk factor for PD. Individuals carrying a heterozygous GBA 
mutation have a five-fold higher risk of developing PD than non-carriers (65). Homozygous 
mutations in this gene cause Gaucher disease (GD), in which the loss of GBA causes 
accumulation of its substrate glucosylceramide within lysosomes, leading to lysosomal dysfunction 
(66). Studies using iPSC-derived neurons from PD patients with GBA mutations showed increased 
α-synuclein levels as well as autophagic and lysosomal defects (67). In non-GBA related PD 
patients, α-syn accumulation impairs trafficking of GBA to lysosomes (68). This suggests a 
possible positive feedback loop, in which loss of GBA leads to impaired lysosomal function and α-
syn accumulation. Inhibition of glycosylceramide synthase (the enzyme that regulates the 
formation of the GBA substrate glucocerebroside) in a mouse model of GBA-related 
synucleinophathy and in mice overexpressing α-syn (A53T) reduced α-syn and ubiquitin 
accumulation in hippocampal neurons and improved cognitive behaviour (69).  
 
Mutations in the gene ATP13A2/PARK9, which encodes a transmembrane lysosomal P-type 
ATPase, cause familial Kufor-Rakeb syndrome characterized by early-onset Parkinsonism (70). 
Mutations in ATP13A2 impair lysosomal function, which manifests with an accumulation of 
lysosomes and autophagosomes (71). Studies in cell models of PD showed that the dopaminergic 
neuron loss caused by α-syn overexpression could be rescued by co-expression of ATP13A2. 
Additionally, knockdown of the ATP13A2 ortholog in C. elegans enhanced α-syn misfolding, 
suggesting a link between α-syn and ATP13A2 (72). This was further supported by a study in 
which loss of ATP13A2 in vitro impaired lysosomal function and led to α-syn accumulation (73). 
The increase in α-syn was, however, not observed in mice, in which loss of ATP13A2 caused 
endolysosomal abnormalities without disrupting α-syn levels (74). Depletion of ATP13A2 in vitro 
led to a decrease in the levels of another PD-associated gene, synaptotagmin 11 (SYT11). The 
9 
 
decrease in SYT11 can account for the lysosomal dysfunction and impaired autophagosome 
degradation resulting from ATP13A2 deficiency, since SYT11 overexpression in ATP13A2 
knockdown cells was able to rescue the autophagy defects in these cells, suggesting that these 
proteins act in the same pathway (15).  
 
Autophagy as a therapeutic strategy 
There is compelling evidence suggesting that impaired trafficking to the lysosome is a common 
mechanism underlying PD pathogenesis and that the aggregate-prone α-syn is an autophagy 
substrate (21,75). Upregulation of autophagy for degradation of aggregate-prone proteins is a 
promising mechanism to protect cells against the toxicity of such proteins and is, therefore, a major 
therapeutic strategy that is being explored (76). 
 
Autophagy can be upregulated by targeting either the mTOR-dependent or mTOR-independent 
pathway. The allosteric mTORC1 inhibitor rapamycin ameliorates toxicity in animal models of PD 
(77,78). Due to its non-ATP-competitive inhibitory properties, rapamycin possesses a safer profile 
than ATP-competitive mTOR inhibitors like Torin1. While rapamycin specifically inhibits mTORC1, 
Torin1 inhibits mTORC1 as well as mTORC2, which is a positive autophagy regulator, thus leading 
to neuronal toxicity rather than protection (77). 
 
Several mTOR-independent compounds that stimulate autophagosome formation have been 
studied for their therapeutic potential (79). Some of those have been shown to induce autophagy 
by stimulating the AMPK pathway, including the FDA-approved compound trehalose, which 
induces autophagy and enhances clearance of α-syn  both in vitro (80) and in vivo (81). Nilotinib, a 
tyrosine kinase inhibitor and AMPK activator protects against loss of DA neurons and improves 
motor behaviour in a mouse model of PD by accelerating autophagic clearance of α-syn (82).  
 
At early stages of disease, pharmacological activation of autophagosome biogenesis may be 
neuroprotective. Such strategies have potential for treating PD variants where increased levels of 
α-syn caused by factors like SNCA multiplication is the underlying mechanism and impairs not only 
autophagosome formation (46), but also endosomal trafficking (83), chaperone-mediated 
autophagy (84) and mitochondrial fusion (85). Indeed, lentiviral delivery of Beclin 1, which is a part 
of the VPS34 complex, into α-syn  transgenic mice reduced α-syn accumulation by inducing  
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autophagosome biogenesis and enhanced lysosomal activation (75). However, inducing 
autophagy may be detrimental, if the presence of α-syn containing inclusion bodies is due to 
impaired autophagosome clearance caused by compromised lysosomal function, as is the case for 
several PD variants. In PD cases with mutations causing impaired autophagosome clearance, an 
upstream induction of autophagosome biogenesis may cause a pathological accumulation of 
autophagosomes and exacerbate disease.  
 
Since α-syn aggregation in some cases of PD is associated with reduced lysosomal capacity 
implied by the impaired trafficking of lysosomal hydrolases (86) and reduction of lysosomal 
markers in nigral DA neurons (87), enhancement of lysosomal capacity through strategies like 
gene therapy may be a promising strategy. A study conducted in a PD model with adeno-
associated virus (AAV) vector-mediated overexpression of human wild-type (WT) α-syn in the rat 
midbrain showed that delivery of the TFEB gene prevents α-syn  induced neurodegeneration (88).  
 
Although autophagy upregulation is a strategy that holds great therapeutic potential, the side-effect 
profiles of many autophagy inducers make them unsuited for long-term treatment due to the 
caveats related to prolonged autophagy upregulation. Development of specialized autophagy 
modulators with tightly regulated mechanisms of action is desirable for effective and differential 
treatment of the subtypes of PD.  
 
 
Concluding remarks 
Treatment of PD is expected to become more personalized in the future, due to the heterogeneity 
in causal elements underlying the vast range of PD variants. This will be facilitated by  
understanding the genetic determinants and molecular mechanisms responsible for the clinical 
phenotype of each PD patient, in order to tailor the most appropriate treatment option towards the 
elements that specifically disrupt autophagy and α-syn clearance in each case. 
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Figure Legends: 
Figure 1. Overview of the autophagy pathway. Low levels of nutrients, growth factors and 
energy levels culminate in inhibition of mTORC1 and AMPK activation. AMPK activates the ULK1 
complex, which subsequently activates the VPS34 complex, resulting in PI3P synthesis. PI3P 
recruits WIPI2 and assists in the recruitment of the ATG12-ATG5-ATG16L1 complex, which is 
essential for the conjugation of LC3-I to PE, leading to membrane elongation and engulfment of 
cytosolic contents. These include aggregate-prone proteins and damaged organelles that 
ultimately are degraded in the lysosome after fusion with autophagosomes. Upregulation of 
autophagy after starvation/mTOR inhibition is in part regulated by translocation of TFEB to the 
nucleus, where it induces transcription of many autophagic and lysosomal genes. AMPK, AMP-
dependent protein kinase; FIP200, focal adhesion kinase family interacting protein of 200kD; 
mTORC1, mammalian target of rapamycin complex 1; PE, phosphatidylethanolamine; PI3P, 
phosphatidylinositol 3-phosphate; TFEB, transcription factor EB; ULK, mammalian homologs of the 
C. elegans uncoordinated-51 kinase. 
Figure 2. PD-related genes associated with the autophagic and endolysosomal pathways. A 
variety of genes associated with sporadic and familial forms of PD are known to affect mitophagy, 
autophagosome biogenesis, lysosomal function and lysosome formation.  
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